Editas prices $125 million follow-on stock offering with warrants at USD 2.25 per unit

Editas Medicine

EDIT

0.00

Editas Medicine priced an underwritten public offering of 55,555,556 common shares with 55,555,556 common stock warrants at a combined price of USD 2.25.
Gross proceeds expected at about USD 125 million before fees, excluding any warrant exercises.
Warrants carry a USD 3.5 exercise price, are exercisable immediately, could raise about USD 194.4 million if fully exercised.
Warrants expire on the earlier of three years or 30 days after specified EDIT-401 Phase 1 LDL-cholesterol data is announced.
Cantor, Wells Fargo Securities acting as joint book-running managers; closing expected on or about May 27, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260905PRIMZONEFULLFEED9726454) on May 26, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.